• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

    6/1/21 4:01:00 PM ET
    $SCL
    $RCEL
    $ANGO
    Package Goods/Cosmetics
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
    Get the next $SCL alert in real time by email

    VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021.

    Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an expatriate General Manager of Baxter Japan and later as General Manager and President of Scimed Life Systems Inc. and Boston Scientific International respectively. During his career he has served as CEO of 3 publicly listed companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), Alphatec Spine (ATEC). Mr. Corbett has also led two privately funded companies as CEO; Home Diagnostics Inc. and Vertos Medical. Mr. Corbett has extensive capital market and governance experience from both public and private environments. Mr. Corbett holds a Bachelor of Science in Business Administration from the University of Kansas.

    Ms. Reed has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Most recently, she was Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions. Prior to Solo Cup Company, she was Associate General Counsel, Corporate Secretary and Chief Corporate Governance Officer at Baxter International, Inc.. Ms. Reed currently serves as a board member of Stepan Co. (NYSE:SCL) and AngioDynamics, Inc. (NASDAQ:ANGO). Ms. Reed holds a Bachelor of Arts degree with honors in Psychology from the University of Michigan and a Juris Doctor from the Northwestern University Pritzker School of Law.

    "We are delighted by the addition of James and Jan to our Board of Directors. They will further strengthen our Board, bringing extensive medical device commercialization, legal and strategic business expertise to Avita," said Lou Panaccio, Chairman of the Board of Avita Medical. "We look forward to leveraging James' experience in running global medical device commercialization efforts as we continue to build market share in burns and beyond, and we expect Jan's breath of executive leadership experience will be invaluable as we continue to execute on our myriad growth objectives."

    About AVITA Medical, Inc.:

    AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

    AVITA Medical's first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient's own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device for a full description of indications for use and important safety information including contraindications, warnings and precautions.

    In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

    For Further Information:

    U.S. Media

    Sam Brown, Inc.

    Christy Curran

    Phone +1-615-414-8668

    [email protected]

    Investors

    Westwicke Partners

    Caroline Corner

    Phone +1-415-202-5678

    [email protected]
      
    O.U.S. Media

    Rudi Michelson

    Phone +61 (0)3 9620 3333

    Mobile +61 (0)411 402 737

    [email protected]
     


    Primary Logo

    Get the next $SCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCL
    $RCEL
    $ANGO

    CompanyDatePrice TargetRatingAnalyst
    Avita Medical Inc.
    $RCEL
    12/24/2024$25.00Buy
    D. Boral Capital
    Avita Medical Inc.
    $RCEL
    4/11/2024Buy → Neutral
    BTIG Research
    AngioDynamics Inc.
    $ANGO
    4/5/2024$12.00Perform → Outperform
    Oppenheimer
    Stepan Company
    $SCL
    10/19/2023$89.00Neutral → Buy
    CL King
    AngioDynamics Inc.
    $ANGO
    9/25/2023$19.00Buy
    H.C. Wainwright
    Avita Medical Inc.
    $RCEL
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    AngioDynamics Inc.
    $ANGO
    4/17/2023$14.00 → $13.00Strong Buy → Outperform
    Raymond James
    Stepan Company
    $SCL
    3/11/2022$9.00 → $8.00Outperform
    RBC Capital
    More analyst ratings

    $SCL
    $RCEL
    $ANGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Stepan Reports First Quarter 2025 Results

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: First Quarter 2025 Highlights Reported net income was $19.7 million, up 42% versus the prior year. Adjusted net income(1) was $19.3 million, up 32% versus the prior year.EBITDA(2) was $58.0 million and Adjusted EBITDA(2) was $57.5 million, up 16% and 12% respectively, year-over-year.Global sales volume was up 4% year-over-year.Cash from Operations was $6.9 million during the quarter. Free cash flow(3) for the quarter was a negative $25.8 million driven by higher working capital to suppor

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Declares Quarterly Dividend

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.385 per share. The dividend is payable on June 13, 2025, to common stockholders of record on May 30, 2025. The Company increased its quarterly cash dividend in the fourth quarter of 2024 by $0.010 per share, marking the 57th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of specialt

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    $RCEL
    $ANGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Stepan Promotes Luis E. Rojo to President and Chief Executive Officer

      NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today announced the appointment of Luis E. Rojo as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. After a 31-year Stepan career, Scott R. Behrens is departing the Company to pursue other opportunities. "We thank Scott for his leadership and his many contributions to the growth and diversification of Stepan over his career with the Company. During his various roles in R&D, sales and marketing, and leadership, he helped diversify our market presence,

      10/30/24 6:55:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • Stepan Company Announces Appointment of New Director

      NORTHBROOK, Ill., Feb. 15, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) announced today the appointment of Susan M. Lewis as a Director of Stepan, effective on February 15, 2024. Ms. Lewis spent over 30 years at Dow Inc., a materials science company, and was part of the management team of Corteva, Inc., a global agriculture company, following its spinoff from DowDuPont Inc. Ms. Lewis served as Senior Vice President, Global Operations of Corteva from 2018 until her retirement in 2021, after which she worked as a business and executive consultant through 2023. Ms. Lewis held senior management roles with operations, sustainability and risk management responsibilities and led organizational r

      2/15/24 4:30:00 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    $RCEL
    $ANGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Lewis Susan bought $31,765 worth of shares (500 units at $63.53), increasing direct ownership by 36% to 1,896 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      2/27/25 8:57:39 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $SCL
    $RCEL
    $ANGO
    Financials

    Live finance-specific insights

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Stepan Reports First Quarter 2025 Results

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: First Quarter 2025 Highlights Reported net income was $19.7 million, up 42% versus the prior year. Adjusted net income(1) was $19.3 million, up 32% versus the prior year.EBITDA(2) was $58.0 million and Adjusted EBITDA(2) was $57.5 million, up 16% and 12% respectively, year-over-year.Global sales volume was up 4% year-over-year.Cash from Operations was $6.9 million during the quarter. Free cash flow(3) for the quarter was a negative $25.8 million driven by higher working capital to suppor

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Declares Quarterly Dividend

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.385 per share. The dividend is payable on June 13, 2025, to common stockholders of record on May 30, 2025. The Company increased its quarterly cash dividend in the fourth quarter of 2024 by $0.010 per share, marking the 57th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of specialt

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    $RCEL
    $ANGO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avita Medical Inc.

      10-Q - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:15:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:05:17 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Stepan Company

      10-Q - STEPAN CO (0000094049) (Filer)

      5/7/25 10:15:10 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    $RCEL
    $ANGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Avita Medical with a new price target

      D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00

      12/24/24 7:10:27 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical downgraded by BTIG Research

      BTIG Research downgraded Avita Medical from Buy to Neutral

      4/11/24 7:58:22 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AngioDynamics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00

      4/5/24 7:36:59 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $SCL
    $RCEL
    $ANGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Supply Chain Haire Robert Joseph exercised 550 shares at a strike of $51.85 and covered exercise/tax liability with 162 shares, increasing direct ownership by 52% to 1,141 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      5/5/25 6:06:02 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Wehmer Edward J exercised 1,865 shares at a strike of $48.07, increasing direct ownership by 33% to 7,449 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      4/15/25 4:10:31 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 4 filed by Director Wehmer Edward J

      4 - STEPAN CO (0000094049) (Issuer)

      4/3/25 4:30:39 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    $RCEL
    $ANGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AngioDynamics Inc.

      SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)

      5/30/24 4:25:33 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      2/13/24 4:58:57 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AngioDynamics Inc. (Amendment)

      SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)

      2/13/24 4:58:53 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care